Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.

Eszter Tichy,Antoni Torres,Matteo Bassetti,Thitima Kongnakorn,Roberto Di Virgilio,Paurus Irani,Claudie Charbonneau

Clinical Therapeutics（2020）

引用 8|浏览7

暂无评分

摘要

The model results showed that CAZ-AVI is expected to provide clinical benefits in hospitalized patients with HAP/VAP in Italy at an acceptable cost compared to meropenem. (Clin Ther. 2020; 42:XXX-XXX) © 2020 Elsevier Inc.

查看译文

关键词

avibactam,CAZ-AVI,ceftazidime,cost-effective analysis,hospital-acquired pneumonia,ventilator-associated pneumonia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要